Tuberculosis

Grant Awarded To Develop Diagnostic Device

Published in TB and Outbreaks Week, May 15th, 2001

Sequella, Inc., announced on April 23, 2001, that it received a Small Business Innovative Research (SBIR) Grant from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) that will drive development of a new diagnostic device for tuberculosis (TB).

This device has the potential to specifically diagnose the disease and evaluate drug resistance of TB organisms within two days, which would represent a major improvement over existing TB diagnostic tools.

The delayed recognition of drug resistance is one of the biggest challenges in the control of drug-resistant TB. Diagnostic methods of evaluating infection and drug resistance often...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2001-05-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry